DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Status
The preliminary amendment filed April 25, 2025 has been received and entered.
Claims 1, 9, 13, and 20 have been amended.
Claims 2-4 have been canceled.
Claims 1 and 5-20 are pending and under consideration.
Priority
Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. This application is a 371 of PCT/KR2023/017306 filed 11/01/2023 which claims the benefit of foreign application KR 10-2022-0144618 filed 11/02/2022.
However, support for the claimed invention cannot be determined because the foreign priority documents provided for KR 10-2022-0144618 are not in English. Applicant cannot rely upon the certified copy of the foreign priority application to overcome any prior art rejection because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216. Failure to provide a certified translation may result in no benefit being accorded for the non-English application.
Accordingly, the PCT/KR2023/017306 filing date of 11/01/2023 will be used for the purpose of applying prior art.
Information Disclosure Statements
The information disclosure statements (IDSs) submitted 04/25/2025, 05/12/2025, 11/17/2025, and 04/08/2026 are in compliance with the provisions of 37 CFR 1.97 except for the following documents which do not have a concise explanation in English. See MPEP 609.04(a)(III).
IDS 04/25/2025
Foreign Patent Document #4 – KR 20180055824 CARSGEN THERAPEUTICS LIMITED (2018-05-25)
Foreign Patent Document #8 – KR 20210108290 GREENCROSSCELL (2021-09-02)
IDS 11/17/2025
Non-Patent Literature Document #2 – Chinese Patent Application No. 202380076442.1 (9/20/2025)
Accordingly, the information disclosure statements are being considered by the examiner, except the documents referenced above.
Specification
The disclosure is objected to because of the following informalities:
The pages of the specification are not numbered.
37 C.F.R. 1.52 (b)(5) states that the pages of the specification including claims and abstract must be numbered consecutively, starting with 1, the numbers being centrally located above or preferably below, the text.
The paragraphs of the specification are not numbered.
37 C.F.R. 1.52 (b)(6) states the paragraphs of the specification, other than in the claims or abstract, may be numbered at the time the application is filed, and should be individually and consecutively numbered using Arabic numerals, so as to unambiguously identify each paragraph.
The number should consist of at least four numerals enclosed in square brackets, including leading zeros (e.g., [0001]). The numbers and enclosing brackets should appear to the right of the left margin as the first item in each paragraph, before the first word of the paragraph, and should be highlighted in bold. A gap, equivalent to approximately four spaces, should follow the number. Nontext elements (e.g., tables, mathematical or chemical formulae, chemical structures, and sequence data) are considered part of the numbered paragraph around or above the elements, and should not be independently numbered. If a nontext element extends to the left margin, it should not be numbered as a separate and independent paragraph. A list is also treated as part of the paragraph around or above the list, and should not be independently numbered . Paragraph or section headers (titles), whether abutting the left margin or centered on the page, are not considered paragraphs and should not be numbered.
Appropriate correction is required.
Claim Objections
Claims 1, 5-8, and 10-20 are objected to because of the following informalities:
Claim 1 (lines 17-18) – should be amended to read “wherein the one or more amino acid substitutions occur at one or more positions selected from the group consisting of: ”.
Claims 1 and 5-7 set forth a plurality of elements. MPEP § 608.01(m) states that each element or step of the claim should be separated by a line indentation. There may be plural indentations to further segregate sub combinations or related steps. Additionally, the elements are numbered within the claim, which makes it hard to distinguish the numbered elements from the claims. It is suggested that the elements be listed using lowercase letters (a, b, and c) or Roman numerals (i, ii, and iii) with each element separated by a line indentation.
Claim 1 (lines 19-21) recite the 1st position, the 7th position, the 1st amino acid and the 7th amino acid. The claim should be amended to read the 1st position, the 7th position, the 1st position and the 7th position using superscript.
Claim 1 (line 21) – add a space in between “NO:” and “19”; correct spacing between “and the” and “7th”.
Claim 1 (line 22) – should read SEQ ID NO: 23.
Claims 6-8 (line 1) – should read “the anti-mesothelin antibody or antigen-binding fragments thereof”.
Claim 8 (line 2) – should read “increases”.
Claims 10-20 – the indentation is inconsistent and differs from the preceding claims.
Claim 12 (line 2) – remove extra spaces after “culturing”.
Claim 12 (line 2) – should read “express the antibody”.
Claim 16 (line 2) – “base sequences” should be amended to “nucleic acid sequences”.
Claim 16 (line 3) – should read “SEQ ID NOs:”.
Claim 19 (line 2) – should read “NK T cell”.
Claim 20 is grammatically awkward and should read “…for preventing or treating mesothelin expressing cancers…”.
Appropriate correction is required.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 1 and 5-20 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
Claim 1 recites “an anti-mesothelin antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region including heavy chain complementarity determining region 1 (HCDR1) including an amino acid sequence consisting of SEQ ID NO:19, heavy chain complementarity determining region 2 (HCDR2) including an amino acid sequence consisting of SEQ ID NO: 20, and a heavy chain complementarity determining region 3 (HCDR3) including an amino acid sequence consisting of SEQ ID NO: 21; and a light chain variable region including light chain complementarity determining region 1 (LCDR1) including an amino acid sequence consisting of SEQ ID NO: 22, light chain complementarity determining region 2 (LCDR2) including an amino acid sequence consisting of SEQ ID NO: 23, and light chain complementarity determining region 3 (LCDR3) including an amino acid sequence consisting of SEQ ID NO: 24…”.
The term “including an amino acid sequence consisting of” makes the claim unclear, as “including” is an open term which allows for the CDRs to comprise additional residue(s) in addition to the recited sequences (SEQ ID NOs). Therefore, the skilled artisan cannot determine the metes and bounds of the claim as presently written.
To obviate the rejection, Applicant may amend the claim to recite “an anti-mesothelin antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence consisting of SEQ ID NO:19, heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence consisting of SEQ ID NO: 20, and a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence consisting of SEQ ID NO: 21; and a light chain variable region including light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence consisting of SEQ ID NO: 22, light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence consisting of SEQ ID NO: 23, and light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence consisting of SEQ ID NO: 24…”.
Claims 5-20 are included in the rejection as they depend from or otherwise require all the limitations of the rejected claim.
Claim 5 recites “the anti-mesothelin antibody or the antigen-binding fragment thereof of claim 1, wherein the anti-mesothelin antibody or the antigen-binding fragment thereof is selected from antibodies or antigen-binding fragments thereof, including a heavy chain variable region including the following heavy chain CDRs and a light chain variable region including the following light chain CDRs:
1) an antibody or an antigen-binding fragment thereof, including: a heavy chain variable region including HCDR1 including an amino acid sequence consisting of SEQ ID NO: 27, HCDR2 including an amino acid sequence consisting of SEQ ID NO: 28, and HCDR3 including an amino acid sequence consisting of SEQ ID NO: 29; and a light chain variable region including LCDR1 including an amino acid sequence consisting of SEQ ID NO: 30, LCDR2 including an amino acid sequence consisting of SEQ ID NO: 31, and LCDR3 including an amino acid sequence consisting of SEQ ID NO: 32,
2) an antibody or an antigen-binding fragment thereof, including: a heavy chain variable region including HCDR1 including an amino acid sequence consisting of SEQ ID NO: 35, HCDR2 including an amino acid sequence consisting of SEQ ID NO: 36, and HCDR3 including an amino acid sequence consisting of SEQ ID NO: 37; and a light chain variable region including LCDR1 including an amino acid sequence consisting of SEQ ID NO: 38, LCDR2 including an amino acid sequence consisting of SEQ ID NO: 39, and LCDR3 including an amino acid sequence consisting of SEQ ID NO: 40, and
3) an antibody or an antigen-binding fragment thereof, including: a heavy chain variable region including HCDR1 including an amino acid sequence consisting of SEQ ID NO: 43, HCDR2 including an amino acid sequence consisting of SEQ ID NO: 44, and HCDR3 including an amino acid sequence consisting of SEQ ID NO: 45; and a light chain variable region including LCDR1 including an amino acid sequence consisting of SEQ ID NO: 46, LCDR2 including an amino acid sequence consisting of SEQ ID NO: 47, and LCDR3 including an amino acid sequence consisting of SEQ ID NO: 48.
The preamble of the claim is confusing as written, and contains redundant information. Additionally, the claim recites VH and VL CDRs that “include” the recited sequences, leaving one to wonder what, if any, additional residues comprise the CDRs.
To obviate the rejection, Applicant may amend the claim to recite “the anti-mesothelin antibody or the antigen-binding fragment thereof of claim 1, wherein the anti-mesothelin antibody or the antigen-binding fragment comprises
1) a heavy chain variable region comprising an HCDR1 amino acid sequence consisting of SEQ ID NO: 27, an HCDR2 amino acid sequence consisting of SEQ ID NO: 28, and an HCDR3 ; and a light chain variable region comprising an LCDR1 amino acid sequence consisting of SEQ ID NO: 30, an LCDR2 amino acid sequence consisting of SEQ ID NO: 31, and an LCDR3 consisting of SEQ ID NO: 32[[,]]; or
2) a heavy chain variable region comprising an HCDR1 amino acid sequence consisting of SEQ ID NO: 35, an HCDR2 amino acid sequence consisting of SEQ ID NO: 36, and an HCDR3 amino acid sequence consisting of SEQ ID NO: 37; and a light chain variable region comprising an LCDR1 amino acid sequence consisting of SEQ ID NO: 38, an LCDR2 amino acid sequence consisting of SEQ ID NO: 39, and an LCDR3 amino acid sequence consisting of SEQ ID NO: 40[[,]]; or
3) a heavy chain variable region comprising an HCDR1 amino acid sequence consisting of SEQ ID NO: 43, an HCDR2 amino acid sequence consisting of SEQ ID NO: 44, and an HCDR3 amino acid sequence consisting of SEQ ID NO: 45; and a light chain variable region comprising an LCDR1 amino acid sequence consisting of SEQ ID NO: 46, an LCDR2 amino acid sequence consisting of SEQ ID NO: 47, and an LCDR3 amino acid sequence consisting of SEQ ID NO: 48.
Claim 6 recites “the anti-mesothelin antibody or the antigen-binding fragment thereof of claim 1, wherein the anti-mesothelin antibody or the antigen-binding fragment thereof is selected from antibodies or antigen-binding fragments thereof including the following heavy chain variable regions and the following light chain variable regions:
1) an antibody or an antigen-binding fragment thereof including a heavy chain variable region including an amino acid sequence consisting of SEQ ID NO: 33 and a light chain variable region including an amino acid sequence consisting of SEQ ID NO: 34;
2) an antibody or an antigen-binding fragment thereof including a heavy chain variable region including an amino acid sequence consisting of SEQ ID NO: 41 and a light chain variable region including an amino acid sequence consisting of SEQ ID NO: 42; and
3) an antibody or an antigen-binding fragment thereof including a heavy chain variable region including an amino acid sequence consisting of SEQ ID NO: 49 and a light chain variable region including an amino acid sequence consisting of SEQ ID NO: 50.
The preamble of the claim is confusing as written, and contains redundant information. Additionally, the claim recites heavy and light chain variable regions “include” the recited sequences, leaving one to wonder what, if any, additional residues comprise the VH and VL.
To obviate the rejection, Applicant may amend the claim to recite “the anti-mesothelin antibody or the antigen-binding fragment thereof of claim 1, wherein the anti-mesothelin antibody or the antigen-binding fragment thereof is selected from antibodies or antigen-binding fragments thereof comprising:
1) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 33 and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 34;
2) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 41 and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 42; or
3) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 49 and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 50.
Claim 7 recites “the anti-mesothelin antibody or the antigen-binding fragment thereof of claim 1, wherein the anti-mesothelin antibody or the antigen-binding fragment thereof is selected from antibodies or antigen-binding fragments thereof including the following antigen-binding fragments:
1) an antibody or an antigen-binding fragment thereof, including an antigen-binding fragment that includes the amino acid sequence consisting of SEQ ID NO: 2;
2) an antibody or antigen-binding fragment thereof, including an antigen-binding fragment that includes the amino acid sequence consisting of SEQ ID NO: 3; and
3) an antibody or an antigen-binding fragment thereof, including an antigen-binding fragment that includes the amino acid sequence consisting of SEQ ID NO: 4.
The preamble of the claim is confusing as written, and contains redundant information. Additionally, the claim preamble recites both antibodies and antibody fragments, however, the claim is directed to antibody fragments, leaving one to wonder what is actually being claimed.
To obviate the rejection, Applicant may amend the claim to recite “the anti-mesothelin antibody or the antigen-binding fragment thereof of claim 1, wherein the anti-mesothelin antigen-binding fragment is selected from :
1) an antigen-binding fragment comprising the amino acid sequence consisting of SEQ ID NO: 2;
2) an antigen-binding fragment comprising the amino acid sequence consisting of SEQ ID NO: 3; and
3) comprising the amino acid sequence consisting of SEQ ID NO: 4.
Claim 8 recites the amino acid substitutions “increases” the affinity of antibody or fragment to its target. The term “increases” is a relative term which renders the claim indefinite. The term “increases” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.
Claim Rejections - 35 USC § 112(a) – Enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claim 20 is rejected under 35 U.S.C. 112(a) because the specification, while being enabling for treating mesothelin expressing cancers with isolated cells that express a chimeric antigen receptor expressing an anti-mesothelin antibody or antigen-binding fragment thereof as recited in claim 1, does not reasonably provide enablement for preventing mesothelin expressing cancers with the instantly claimed antibodies and antibody fragments as broadly claimed.
The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
As a general rule, enablement must be commensurate with the scope of claim language. MPEP § 2164.08 states, “The Federal Circuit has repeatedly held that “the specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation.” In re Wright, 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)” (emphasis added). The “make and use the full scope of the invention without undue experimentation” language was repeated in 2005 in Warner-Lambert Co. v. Teva Pharmaceuticals USA Inc., 75 USPQ2d 1865, and Scripps Research Institute v. Nemerson, 78 USPQ2d 1019 asserts: “A lack of enablement for the full scope of a claim, however, is a legitimate rejection.” The principle was explicitly affirmed in Auto. Tech. Int’l, Inc. v. BMW of N. Am., Inc., 501 F.3d 1274, 84 USPQ2d 1108 (Fed. Cir. 2007), Monsanto Co. v. Syngenta Seeds, Inc., 503 F.3d 1352, 84 U.S.P.Q.2d 1705 (Fed. Cir. 2007), and Sitrick v. Dreamworks, LLC, 516 F.3d 993, 85 USPQ2d 1826 (Fed. Cir. 2008). See also In re Cortright, 49 USPQ2d 1464, 1466 and Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer Inc., 49 USPQ2d 1370.
The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature or the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner’s position that one skilled in the art could not practice the invention without undue experimentation. Some experimentation is not fatal; the issue is whether the amount of experimentation is “undue”; see In re Vaeck, 20 USPQ2d 1438, 1444.
(1) The nature of the invention and (5) The breadth of the claims:
Claim 20 is drawn to a pharmaceutical composition for preventing or treating cancer expressing mesothelin with a cell expressing an anti-mesothelin chimeric antigen receptor comprising an anti-mesothelin antibody fragment comprising the amino acid sequences recited in claim 1.
(2) The state of the prior art and (4) The predictability or unpredictability of the art:
The breadth of the claims exacerbates the complex nature of the subject matter to which the present claims are directed. The state of the art teaches that mesothelin is an oncogenic driver that promotes cell survival, decreases apoptosis, and metastasis. And although targeting MSLN has been demonstrated to decrease tumor growth and metastasis in several cancer types (Boisgard et al., 2026), the state of the art teaches there is no known anticancer agent that can prevent any type of cancer.
The art of cancer prevention involves a very high level of unpredictability. While the state of the art is relatively high with regard to the treatment of specific cancers with specific agents, it has long been underdeveloped with regard to the prevention of cancers broadly. The lack of significant guidance from the present specification or prior art with regard to the actual prevention of cancer in a subject, with the claimed active ingredient makes practicing the claimed invention unpredictable.
With regard to cancer prevention, Umar et al. (2012) teaches cancer prevention remains a promising strategy for reducing the mortality and incidence rates of cancer, however, prevention is more about reducing risk factors than it is about eliminating cancer [Abstract]. In addition, both Umar and Bode et al. (2009), teach cancer prevention is not about eliminating cancer altogether, but reducing risk factors and exposure with the goal of inhibiting progression of cancer to more invasive stages [Umar; pg. 835, col. 2, par. 2; pg. 836, col. 1, par. 2; pg. 839, col. 2, par. 2-3] [Bode; pg. 511, col. 3, par. 2]. Moreover, Sarfati et al. (2022) teaches that primary prevention of cancer through eradication or mitigation of modifiable risk factors is the best hope of reducing the future cancer burden [pg. 541, col. 1]. For example, Umar teaches stopping tobacco use is one lifestyle change that can reduce both the risk of selected cancers and other diseases but does not completely (i.e., 100%) prevent cancer [pg. 836, col. 1, par. 2]. Importantly, even vaccination has yet to achieve 100% prevention, as seen with the hepatitis B virus (HBV) vaccine. The vaccine is aimed at reducing HBV infections and subsequent hepatocellular cancer (HCC), and has an estimated 69% reduction rate in prevention HBV-HCC [Umar; pg. 842, col. 1, par. 3), not 100% prevention. Although cancer vaccines can serve as preventive measures in high-risk populations and provide treatment options for individuals already diagnosed with cancer [Kaczmarek et al., 2023; pg. 2, par. 2], they also face a myriad of obstacles depending on the target, type of vaccine, delivery method, and type of cancer (Kaczmarek et al., pg. 21, section 7).
Given the lack of predictability in preventing cancer, one of skill in the art would have to engage in undue experimentation to identify which of the instantly claimed anti-mesothelin antibody or antigen-binding fragments thereof that would effectively prevent mesothelin expressing cancers.
(3) The relative skill of those in the art:
The relative skill in the art is high for those with an M.D. or Ph.D.
6) the amount of direction or guidance provided by the inventor; 7) the existence of working examples;
Examples 4-5 of the instant specification demonstrates the results of in vitro experiments with mesothelioma, ovarian cancer, and pancreatic cells treated with the instantly claimed anti-MSLN CAR T cells, wherein the chimeric antigen receptor displayed cytotoxic activity against the target cells [pg. 42-44]. Example 6 of the instant specification demonstrates the results of in vivo experiments mice bearing pancreatic tumors treated with the instantly claimed anti-MSLN CAR T cells, resulting in a 93% reduction in tumor volume [pg. 45-49].
However, these experiments only suggest that the instantly claimed anti-mesothelin antibody or antigen-binding fragment thereof, or a chimeric antigen receptor expressing said antibody, can treat mesothelin expressing cancers, not prevent it. Therefore, the only embodiment that is enabled is treatment of mesothelin-expressing cancer. One of skill in the art would be required to engage in extensive, difficult experimentation to first develop criteria for identification of types of anti-MSLN antibodies or antibody fragments to which the method can apply which is known to be unpredictable as indicated above. This required experimentation is undue.
In conclusion, the claimed invention does not provide enablement for prevention of a mesothelin-expressing cancer. Thus for the reasons outlined above, the specification is not considered to be enabling for one skilled in the art to make and use the claimed invention as the amount of experimentation required is undue, due to the broad scope of the claims, the lack of guidance and working examples provided in the specification. Therefore, the specification is not representative of the instant claims and the specification is not fully enabled for the instant claims. In view of the above, one of skill in the art would be forced into undue experimentation to practice the claimed invention.
Statement Regarding Prior Art
Claim 1 is drawn to an anti-mesothelin antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence consisting of SEQ ID NO:19, heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence consisting of SEQ ID NO: 20, and a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence consisting of SEQ ID NO: 21; and a light chain variable region including light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence consisting of SEQ ID NO: 22, light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence consisting of SEQ ID NO: 23, and light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence consisting of SEQ ID NO: 24, wherein the heavy chain variable region and the light chain variable region include one or more amino acid substitutions, and wherein the one or more amino acid substitutions occur at one or more positions selected from the group consisting of: (a) the 1st position of SEQ ID NO: 19 is substituted from D to L, (b) the 7th position of SEQ ID NO: 23 is substituted from S to R, and (c) the 1st position of SEQ ID NO: 19 is substituted from D to L, and the 7th position of SEQ ID NO: 23 is substituted from S to R.
There is no prior art that teaches or suggests an anti-mesothelin antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and the light chain variable region comprising one or more amino acid substitutions wherein the 1st position of SEQ ID NO: 19 is substituted from D to L, and/or the 7th position of SEQ ID NO: 23 is substituted from S to R.
The closest prior art, An (US Patent No. 11,795,215), teaches a chimeric antigen receptor comprising an anti-mesothelin antigen-binding fragment, comprising a heavy chain variable region comprising heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence consisting of SEQ ID NO: 1, heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence consisting of SEQ ID NO: 2, and a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence consisting of SEQ ID NO: 3; and a light chain variable region including light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence consisting of SEQ ID NO: 4, light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence consisting of SEQ ID NO: 5, and light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence consisting of SEQ ID NO: 6, corresponding to the recited anti-MSLN antibody recited in the instant claims, without the amino acid substitutions in the heavy chain variable region and the light chain variable region, i.e., wherein the 1st position of SEQ ID NO: 1 is substituted from D to L, and/or the 7th position of SEQ ID NO: 5 is substituted from S to R.
Conclusion
No claim is allowed.
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MAUREEN DRISCOLL whose telephone number is (571) 270-0730. The examiner can normally be reached Monday through Friday.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached on (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call (800) 786-9199 (IN USA OR CANADA) or (571) 272-1000.
/MAUREEN VARINA DRISCOLL/ Examiner, Art Unit 1642
/SAMIRA J JEAN-LOUIS/Supervisory Patent Examiner, Art Unit 1642